Evidence map›Paper›PMID 26398076›Full record

ArticleThe New England journal of medicine2015

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

James Larkin, F Stephen Hodi, Jedd D Wolchok

Erratum issued 3 registry-linked trialsAbstract readLetterComment
PubMed Publisher
In one paragraph

Article in The New England journal of medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 3 registered trials, which are not on this map. Cited by 492 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
492citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03233152 phase1 / phase2active not recruitingnot on this mapstarted 2016, after this paper: background citation

A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma

TypeinterventionalSponsorUniversitair Ziekenhuis BrusselRan2016 to 2026Enrolled110ConditionsGlioblastomaArmsIpilimumab (YervoyTM, 50 mg/10 mL solution), Nivolumab (OpdivoTM, 40 mg/4mL solution), Autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ myDC
NCT03894215 phase2terminatednot on this mapstarted 2019, after this paper: background citation

A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS

TypeinterventionalSponsorAgenus Inc.Ran2019 to 2025Enrolled211ConditionsCervical CancerArmsAGEN2034, AGEN1884
NCT04250246 phase2unknown statusnot on this mapstarted 2020, after this paper: background citation

A Randomized, run-in, Multi-center, Phase II Study of Nivolumab Combined With Ipilimumab and Guadecitabine or Nivolumab Combined With Ipilimumab in Melanoma and NSCLC Patients Resistant to Anti-PD-1/PD-L1 (NIBIT-ML1)

TypeinterventionalSponsorItalian Network for Tumor Biotherapy FoundationRan2020 to 2025Enrolled184ConditionsMelanoma, Non Small Cell Lung CancerArmsIpilimumab plus nivolumab plus guadecitabine, Ipilimumab plus nivolumab
3 · Its place in the literature

Who cites it

492 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. SEOM clinical guideline for the management of cutaneous melanoma (2020).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Guideline
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Triplet Strategies in Metastatic Clear Cell Renal Cell Carcinoma: A Worthy Option in the First-Line Setting?American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2023
    Trial
  15. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With AdvancedJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

432 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

James Larkin
F Stephen Hodi
Jedd D Wolchok

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMelanomaSkin NeoplasmsAntibodies, Monoclonal

Identifiers

PMID26398076

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.